Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/265"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"06/09/2009 19:55:20"
|
| ?:content |
"Route of administration: oral
study duration: not mentioned
population: 14 CYP2D6 extensive metabolizers (adults inferred)
ages: mean(std dev): not mentioned
Quote:
Ketoconazole: A pharmacokinetic study with ketoconazole 100 mg b.i.d. with a single dose of venlafaxine 50 mg in extensive metabolizers (EM; n = 14) and 25 mg in poor metabolizers (PM; n = 6) of CYP2D6 resulted in higher plasma concentrations of both venlafaxine and O‑desvenlafaxine (ODV) in most subjects following administration of ketoconazole. Venlafaxine Cmax increased by 26% in EM subjects and 48% in PM subjects. Cmax values for ODV increased by 14% and 29% in EM and PM subjects, respectively.
Venlafaxine AUC increased by 21% in EM subjects and 70% in PM subjects (range in PMs � 2% to 206%), and AUC values for ODV increased by 23% and 141% in EM and PM subjects (range in PMS � 38% to 105%) subjects, respectively. Combined AUCs of venlafaxine and ODV increased on average by approximately 23% in EMS and 53% in PMs (range in PMs � 4 to 134%)."
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ketoconazole_increases_auc_O-desmethylvenlafaxine, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1012 }